Doxorubicin Hydrochloride Injectable, Liposomal
Product Images NDC 68001-703

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 68001-703). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 01)

Chemical structure diagram of doxorubicin hydrochloride, illustrating the molecular configuration including rings, hydroxyl groups, methoxy group, amino group, and the hydrochloride component.*

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 02)

Chemical structure diagram showing the molecular structure of polyethylene glycol (PEG) and related components, likely representing a component of a liposomal formulation such as in doxorubicin hydrochloride liposomal injectable product by BluePoint Laboratories.*

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 03)

Chemical structure diagram showing the molecular structure of the active ingredient doxorubicin hydrochloride, with annotations indicating variable chain lengths (m, n = 14 or 16).*

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 04)

An illustration diagram showing the structure of liposomal doxorubicin hydrochloride. It depicts an aqueous core with entrapped doxorubicin HCl at the center, surrounded by a liposomal bilayer, and an outer MPEG-DSPE coating layer.*

FDA Label Image

Vial Label- Doxorubicin HCl Liposome Injection 20mg/10 mg (6ba8cf1f 0639 4db5 A864 37077551bb70 05)

DOXOrubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) in a single-dose vial, injectable liposomal formulation for intravenous use. Label highlights cytotoxic nature, requirement for dilution prior to infusion, and storage instructions to refrigerate at 2° to 8°C and not freeze. Manufactured by BluePoint Laboratories.*

FDA Label Image

Carton (Doxorubicin HCL Liposome Injection 20mg/10ml)

The packaging label for DOXOrubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) by BluePoint Laboratories. It is a sterile, single-dose vial for intravenous infusion that must be diluted before use. The label highlights its liposomal formulation and refrigeration storage requirements at 2° to 8°C, with a warning not to freeze.*

FDA Label Image

Vial Label (Doxorubicin HCL Liposome Injection 50mg/25ml)

DOXOrubicin Hydrochloride Liposome Injection 50 mg/25 mL (2 mg/mL) injectable solution in a 25 mL single-dose vial by BluePoint Laboratories. The label indicates it is a cytotoxic agent requiring dilution, for intravenous infusion only after dilution, and includes storage instructions to refrigerate and not freeze. Contains warnings against substitution and unused portion discard.*

FDA Label Image

Carton (Doxorubicin HCL Liposome Injection 50mg/25ml)

DOXOrubicin Hydrochloride Liposome Injection 50 mg/25 mL (2 mg/mL) injectable liposomal formulation in a 25 mL single-dose vial. Label indicates it is for intravenous infusion only after dilution, cytotoxic agent, sterile, and should be refrigerated at 2° to 8°C. Manufactured by BluePoint Laboratories with caution not to substitute this liposomal formulation for doxorubicin hydrochloride.*

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 130 2)

A Kaplan-Meier survival curve chart showing the percent of subjects progression-free over time in months, comparing two treatments: Doxorubicin + Bortezomib versus Bortezomib alone. The chart includes censored data points and a table below indicating the number of subjects at risk at various time points for each treatment group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.